Align Technology
ALGNWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $163.96 (close on November 18) and with the other assumptions at their starting point, Align Technology's sales would need to grow 9.8% a year for ten years; over its last decade, the median was 13.0%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 846 | — | 28.6% |
| 12/2016 | 1,080 | 27.7% | 28.1% |
| 12/2017 | 1,473 | 36.4% | 28.0% |
| 12/2018 | 1,966 | 33.5% | 27.3% |
| 12/2019 | 2,407 | 22.4% | 26.2% |
| 12/2020 | 2,472 | 2.7% | 19.6% |
| 12/2021 | 3,953 | 59.9% | 27.6% |
| 12/2022 | 3,735 | −5.5% | 20.8% |
| 12/2023 | 3,862 | 3.4% | 20.6% |
| 12/2024 | 3,999 | 3.5% | 19.5% |
| 12/2025 | 4,035 | 0.9% | 18.1% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Align Technology files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 3.4% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 19.5% of sales.
- Working capital needed to grow: −$9.9 per $100 of new sales.
- Capital spending: 4.6% of sales.
- Stock pay to employees: 2.7% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- It has more cash than debt.
- Its sales grew 16.9% a year on average over 10 years, from $0.8 billion to $4.0 billion; the median of grinboss companies is 6.6%.
- Growing brings it cash: it collects from its customers before it pays its suppliers.
- It sold more than the year before in 9 of the last 10 years.
Against
- Its margin has fallen over these years, from 28% to 20%.
- Over ten years it fell as much as 83% from its high; the median is 56%.
- It is one of the smallest in grinboss: it sells $4.0 billion a year; the median is $15.1 billion.
- Its share price amplifies the market's moves: a five-year beta of 1.61; the median is 0.94.
Next results: February 3, 2027.
Other companies in its sector (Health Care)
Alnylam Pharmaceuticals (ALNY) · Amgen (AMGN) · Baxter International (BAX) · Becton Dickinson (BDX) · Biogen (BIIB) · Bristol Myers Squibb (BMY) · Boston Scientific (BSX) · Cardinal Health (CAH) · All companies
Loading the model…